延长瑞莎珠单抗治疗对溃疡性结肠炎诱导无应答患者的疗效
在INSPIRE诱导研究中,209例对12周静脉瑞莎珠单抗1200mg诱导无临床应答的中重度溃疡性结肠炎患者被重新随机分配接受额外12周1200mg静脉或180mg/360mg皮下瑞莎珠单抗治疗。第24周时,三组临床应答率分别为50%、56.3%和57.1%,360mg组疗效普遍最高;延迟应答者在维持治疗第52周保持临床缓解并改善内镜结局,安全性特征与已知一致。
要点
- 对12周瑞莎珠单抗诱导无应答的UC患者,延长治疗至24周可使超50%获得临床应答。
- 360mg皮下组在临床应答、内镜改善等多项结局上数值最高。
- 延迟应答者维持治疗至52周临床缓解持续,内镜结局改善。
核心结论
- 超50%的初始无应答者经延长瑞莎珠单抗治疗获得临床应答。
- 延长治疗还获得额外临床和内镜结局,维持治疗后疗效持续或改善。
- 延长治疗耐受良好,未发现新安全性风险。
研究设计与样本
- 3期INSPIRE诱导研究中对12周静脉瑞莎珠单抗1200mg无临床应答的209例中重度活动性UC患者重新随机。
- 患者双盲接受额外12周1200mg静脉(第12、16、20周)或180mg/360mg皮下(第12、20周)瑞莎珠单抗。
- 对皮下瑞莎珠单抗第24周临床应答的延迟应答者(来自2b期和3期)继续在3期COMMAND维持研究中按分配剂量接受盲法治疗。
- 在第24周诱导和第52周维持时评估疗效与安全性。
主要发现
- 初始无应答者(1200mg IV n=68,180mg SC n=71,360mg SC n=70)第24周临床应答率分别为50%、56.3%、57.1%。
- 临床缓解和组织学内镜下黏膜改善率分别为8.8%、12.7%、15.7%(两个终点相同)。
- 内镜改善率分别为17.6%、18.3%、24.3%,内镜缓解率分别为1.5%、8.5%、5.7%。
- 360mg组疗效率普遍最高。
- 维持治疗中延迟应答者第52周临床缓解率持续,内镜结局和组织学内镜下黏膜改善率增加。
临床怎么用
- 对12周瑞莎珠单抗诱导无应答的UC患者,可考虑延长治疗12周后再评估应答。
- 延长治疗期间可评估临床应答、临床缓解、内镜改善及组织学内镜下黏膜改善等多项结局。
- 延迟应答者进入维持治疗后应继续监测疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The efficacy and safety of extended induction treatment with risankizumab, an interleukin-23 p19 inhibitor, in patients with moderately to severely active ulcerative colitis (UC) who, per site evaluation, did not achieve clinical response to 12 weeks of risankizumab induction was evaluated. METHODS: In the phase 3 INSPIRE induction study, 209 initial nonresponders to 12 weeks of 1200 mg intravenous (IV) risankizumab induction were rerandomized to receive 12 weeks of additional 1200 mg risankizumab (weeks 12, 16, and 20) or 180 mg or 360 mg subcutaneous [SC] risankizumab (weeks 12 and 20) in a double-blind fashion. Patients from both phase 2b and 3 with week 24 clinical response to SC risankizumab (delayed responders) continued to receive blinded risankizumab at their assigned dose in the phase 3 COMMAND maintenance study. Efficacy and safety were evaluated at week 24 of induction and week 52 of maintenance. RESULTS: Initial nonresponders (1200 mg IV [n = 68], 180 mg SC [n = 71], or 360 mg SC [n = 70]) had week 24 clinical response rates of 50%, 56.3%, and 57.1%, respectively; patients also achieved clinical remission, histologic endoscopic mucosal improvement (8.8%, 12.7%, and 15.7% for both endpoints), endoscopic improvement (17.6%, 18.3%, and 24.3%), and endoscopic remission (1.5%, 8.5%, and 5.7%). Efficacy rates were generally highest with 360 mg. In maintenance, delayed responders demonstrated sustained rates of clinical remission and increased rates of endoscopic outcomes and histologic endoscopic mucosal improvement at week 52. The safety with extended risankizumab treatment was consistent with the known risankizumab safety profile. CONCLUSIONS: Over 50% of initial nonresponders achieved clinical response with extended risankizumab treatment. Additional clinical and endoscopic outcomes were also achieved, with sustained or improved efficacy observed following maintenance. Extended treatment was well tolerated with no new safety risks identified. ClincialTrials.gov, Numbers. NCT03398148 (INSPIRE), NCT03398135 (COMMAND).
引用
- Panaccione R, Melmed GY, Drobne D, et al. Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. Clin Gastroenterol Hepatol. 2025. PMID: 40953785. doi:10.1016/j.cgh.2025.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。